Medindia

X

China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations

Friday, September 18, 2009 General News J E 4
Advertisement
SHANGHAI, July 31 China-Biotics, Inc.(Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firmspecializing in the manufacture, research, development, marketing anddistribution of probiotics products, today announced it has submittedapplications for four patents to the State Intellectual Property Office of thePeople's Republic of China.

These applications are patents for a protein powder formulation; homeyogurt fermentation, a retail powder that enables customers to make yogurt athome; a yogurt powder; and a health-enhancing yogurt. All of theseapplications are for probiotics-based products. Currently, the IntellectualProperty Office is conducting an official review of these applications. Ittakes about two years to obtain patent certificates under normal circumstances.

"These four new formulations are the result of sustained productdevelopment by our highly skilled staff of more than 30 researchers withadvanced degrees and our extensive relationships with academic institutions,"said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics.

The Company also announced that Mr. Zhenjia Bian and Mr. Chengdong Yi,senior officials from the State Food and Drug Administration, visited theCompany recently. The visit coincided with China's new umbrella food safetylaw, which sets more stringent standards for food production throughout China.The officials praised the Company's significant achievements in probioticsapplications during the past decade and encouraged management to continue itsbusiness expansion efforts.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leadingmanufacturer of biotechnology products and supplements, engages in theresearch, development, marketing and distribution of probiotics dietarysupplements. Through its wholly owned subsidiary, Shanghai ShiningBiotechnology Co., Ltd., the Company has operations in Shanghai. Itsproprietary product portfolio contains live microbial nutritional supplementsunder the "Shining" brand. Currently, the products are sold OTC through largedistributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang.China-Biotics plans to launch 300 Shining brand retail outlets in major citiesin China. Currently, China-Biotics is strategically expanding its productioncapacity of probiotics to meet growing demand in the bulk additive market.For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Actof 1995: Any statements set forth above that are not historical facts areforward-looking statements that involve risks and uncertainties that couldcause actual results to differ materially from those in the forward-lookingstatements. Such factors include, but are not limited to, the Company'sability to obtain the patents applied for, market existing and new productsand changes from anticipated levels of sales, future national or regionaleconomic and competitive conditions, market acceptance of its retail storeconcept, changes in relationships with customers, dependence on its flagshipproduct profits and other factors detailed from time to time in the Company'sfilings with the United States Securities and Exchange Commission and otherregulatory authorities. The Company undertakes no obligation to publiclyupdate or revise any forward-looking statements, whether as a result of newinformation, future events or otherwise.For more information, please contact: CCG Investor Relations Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: crocker.coulson@ccgir.com Web: http://www.ccgirasia.com

SOURCE China-Biotics, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
NxStage to Present at the Canaccord Adams Global G...
S
Lilly Announces Continued Commitment to Transparen...